eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2018
vol. 35
 
Share:
Share:
more
 
 
abstract:
Letter to the Editor

Delayed allergy to acyclovir revealed by lymphocyte proliferation test

Marcello Albanesi, Attilio Di Girolamo, Vincenzo Aresta, Maria Pia Rossi, Lucia Giliberti, Tommasina Perrone, Danilo Di Bona, Maria Filomena Caiaffa, Giorgina Specchia, Luigi Macchia

Adv Dermatol Allergol 2018; XXXV (5): 527-529
Online publish date: 2018/07/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Acyclovir (Acycloguanosine) is an antiviral drug commonly used in the management of the Herpes virus infections. Indeed, acyclovir has the unique property of inhibiting viral DNA polymerases and, thereby, decreasing the production of viral particles. Acyclovir can be administered by a topical, oral or intravenous route, depending on clinical circumstances. Importantly, in the case of haematological malignancies, acyclovir can be used after either chemotherapy or stem cell transplantation, in order to prevent Herpes virus reactivation [1]. So far, immediate allergic reactions to acyclovir have been described [2]. In contrast, delayed allergy to acyclovir remains anecdotal [3].
Here we report a case of an adult patient diagnosed with non-Hodgkin lymphoma who developed severe delayed hypersensitivity to oral acyclovir administration. The adverse reaction was revealed using a non-radioactive lymphocyte proliferation test (LPT).
A 62-year-old man was diagnosed with non-Hodgkin lymphoma in 2014. In May 2016, he underwent autologous haematopoietic stem cell transplantation, followed by an oral acyclovir treatment course (1200 mg/day, for 7 days), to prevent Herpes virus reactivation (IgG anti-Herpes simplex 1–2 29.1 U/ml; IgG anti-Epstein Barr virus 30.4 U/ml). This treatment was well tolerated.
In November 2016, due to a relapse of the non-Hodgkin lymphoma, the patient started treatment with bendamustine and rituximab. This treatment was followed by an oral acyclovir course at the same dosage as above. However, after 10 days, the patient developed a generalized cutaneous rash characterized by erythematous, long-lasting and intensively itchy lesions (Figure 1 A). For this reason, the treatment with acyclovir was stopped and treatment with prednisone 5 mg/day and fexofenadine hydrochloride 180 mg b.i.d. was established.
In December 2016, the patient underwent another treatment course with bendamustine and rituximab; however no antiviral treatment was administered following this latter treatment course. Importantly, the patient did not develop any adverse reactions.
Thereby, based on the clinical symptoms manifested, the time of onset of the adverse reaction and the resolution of the clinical condition upon treatment withdrawal and steroid treatment, we postulated the diagnosis of delayed hypersensitivity to acyclovir.
Thus, the case was further investigated using both patch tests and LPT. The patch tests performed with a 25...


View full text...
references:
Styczynski J, Reusser P, Einsele H, et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 2009; 43: 757-70.
Snape SE, Finch RG, Venkatesan P. Acyclovir desensitisation and rechallenge. BMJ Case Rep 2011; 2011: pii: bcr1020103392.
Robinson GE, Weber J, Griffiths C, et al. Cutaneous adverse reactions to acyclovir: case reports. Genitourin Med 1985; 61: 62-3.
Bomgaars L, Thompson P, Berg S, et al. Valacyclovir and acyclovir pharmacokinetics in immunocompromised children. Pediatr Blood Cancer 2008; 51: 504-8.
Porebski G, Gschwend-Zawodniak A, Pichler WJ. In vitro diagnosis of T-cell mediated drug allergy. Clin Exp Allergy 2011; 41: 461-70.
Meerbach A, Wutzler P, Gruhn B. Brivudin (ZostexR) in the treatment of Herpes zoster in immunosoppressed patients. Antivir Res 2007; 74: A75.
Wutzler P, De Clercq E, Wutke K, Färber I. Oral brivudin vs. intravenous acyclovir in the treatment of herpes zoster in immunocompromised patients: a randomized double-blind trial. J Med Virol 1995; 46: 252-7.
Pichler WJ. The p-i concept: pharmacological interaction of drugs with immune receptors. World Allergy Organ J 2008; 1: 96-102.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe